FDA Science Board Advisory Committee Meeting

November 5, 2004 5630 Fishers Lane, Room 1066

8:00 a.m. Call to Order Kenneth I. Shine, M.D., Chair, FDA Science Board **Meeting Statement** Jan N. Johannessen, Ph.D., Executive Secretary 8:10 a.m. Welcome and opening remarks Lester M. Crawford, D.V.M., Ph.D., Acting Commissioner of Food and Drugs 8:25 a.m. Update on the Critical Path Initiative **CDER Critical Path Activities** Douglas Throckmorton, M.D., Center for Drug Evaluation and Research, FDA **CBER Critical Path Activities** Jesse Goodman, M.D., M.P.H., Director, Center for Biologics Evaluation and Research, FDA **CDRH Critical Path Activities** Daniel Schultz, M.D., Director, Center for Devices and Radiological Health, FDA **Overview of Critical Path Docket Submissions** Lisa Rovin, J.D., Director, Critical Path Initiative, Office of the Commissioner, FDA 9:30 a.m. Break 9:45 a.m. Critical Path - Current Activities and The Path Forward Janet Woodcock, M.D., Acting Deputy Commissioner for Operations, FDA 10:15 a.m. Medical Technology Innovation Task Force Larry G. Kessler, Sc.D., Director, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, FDA **Foods Critical Path White Paper** 10:45 a.m. Alan M. Rulis, Ph.D., Senior Advisor for Special Projects, Center for Food Safety and Applied Nutrition, FDA 11:00 a.m. Questions and Discussion with the Board/Presenters 12:00 p.m. Lunch 1:00 p.m. **Open Public Hearing** 2:00 p.m. Pharmaceutical cGMP Initiative Janet Woodcock, M.D., Acting Deputy Commissioner for Operations, FDA Final Report on Process Analytical Technology and Manufacturing Science Ajaz Hussain, Ph.D., Deputy Director, Office of Pharmaceutical Sciences, CDER, FDA 3:30 p.m. Break **ORA Peer Review - Overview of Report and Plan for External Peer Review** 3:45 p.m. John R. Marzilli, Deputy Associate Commissioner for Regulatory Affairs, FDA **Questions and Discussion with Board - Recommendations** 4:30 p.m. 5:00 p.m. Adjourn